Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.

Launched by AALBORG UNIVERSITY HOSPITAL · Jan 28, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how different factors like gender, smoking, and obesity affect how well patients with certain types of arthritis respond to specific treatments called TNF inhibitors. These treatments, like infliximab and adalimumab, help reduce inflammation and manage symptoms in patients diagnosed with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. The researchers want to understand if higher levels of inflammation, specific genetic markers, and the presence of certain antibodies impact treatment effectiveness.

To participate in this study, you need to be over 18 years old and have been diagnosed with one of the mentioned types of arthritis. You should be starting treatment with infliximab or adalimumab, and it’s okay if you are also taking other medications to help manage your condition. While the study is currently recruiting participants, you’ll have the chance to contribute to important research that could improve treatment options for arthritis patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients \> 18 years
• • Diagnosed with RA, PsA or AS.
• • Starting treatment with infliximab or adalimumab.
• • Co- treatment with csDMARD or glucocorticoid is acceptable.
• • No new bDMARD is initiated at the time of sampling.
• Exclusion Criteria:
• • -